Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARPAC2: gemcitabine + nab-paclitaxel with or without ATRA in locally advanced treatment-naive pancreatic cancer
ISRCTN11503604Phase 2Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, paclitaxel and tretinoin in pancreatic adenocarcinoma (PDAC), sponsored by Queen Mary University of London. Started Apr 2020; status: recruiting.
02
Drugs
gemcitabinepaclitaxeltretinoin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN11503604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11503604.